Brief: Helix Biopharma Corp accelerates escalation of l-dos47 dosing in the U.S. early-stage study

Helix Biopharma

30/11/2016 12:33

Nov 30 (Reuters) - Helix Biopharma Corp  HBP.TO - 
    * Helix Biopharma Corp accelerates escalation of l-dos47 
dosing in the U.S. Phase I study 
    * FDA accepted accelerated escalation scheme for l-dos47 
dosing in U.S. Phase I study (ldos001) up to 12g/kg with 
pemetrexed/carboplatin 
 
Source text for Eikon:  ID:nMKW5Dfh4a  
Further company coverage:  HBP.TO  
 
 ((bangalore.newsroom@thomsonreuters.com;))